Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes. Researchers aim to understand if ctDNA detection can identify patients at higher risk of recurrence and guide better treatment decisions. A key aspect is the inclusion of a dedicated cohort of African American/Black women, a group underrepresented in molecular residual disease (MRD) research despite experiencing more aggressive breast cancers. This study will correlate ctDNA results with treatment patterns (radiotherapy, systemic therapy) and outcomes (recurrence-free and overall survival) in both non-African American and African American participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana zgoda na uczestnictwo w badaniu i autoryzacja dostępu do danych zdrowotnych
- •Gotowość i możliwość uczestnictwa w badaniu selon opinią badacza
- •Wiek co najmniej 18 lat w momencie wyrażenia zgody
- •Przeprowadzona operacja chirurgiczna i posiadanie próbek tkanki z guza lub węzła chłonnego do analiz laboratoryjnych
✗ Disqualifies
- •Wcześniejsze leczenie chemio- lub radioterapią przed operacją
- •Stwierdzenie przerzutów w badaniach obrazowych
- •Obecność mikroskopijnych komórek nowotworowych w węzłach chłonnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, United States
Trial contact
Timothy H Wilkinson
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.